Trastuzumab (Herceptin™) in metastatic transitional cell carcinoma of the urinary tract: Report on six patients

European Urology

Volumn 48, Issue 5, 2005, Pages 771-778

  Peyromaure, Michaël ^a   Scotté, Florian ^b   Amsellem Ouazana, Delphine ^a   Vieillefond, Annick ^a   Oudard, Stéphane ^b   Beuzeboc, Philippe ^a  

^a Cochin Hospital ^*  (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Bladder cancer; c erbB 2; HER2; Therapeutic target; Urothelial tumor

Indexed keywords

CARBOPLATIN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ANUS DISEASE; ARTICLE; BLADDER CARCINOGENESIS; BLADDER METASTASIS; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY PELVIS CARCINOMA; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URINARY TRACT CARCINOMA; URINARY TRACT INFECTION; VOMITING; AGED; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PILOT STUDY; RETROSPECTIVE STUDY; URINARY TRACT CANCER;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PILOT PROJECTS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 27144451261     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.07.015     Document Type: Article

References (15)

1. J.E. Gschwend, P. Dahm, and W.R. Fair Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy Eur Urol 41 2002 440 448
2. H. Nishiyama, T. Habuchi, J. Watanabe, S. Teramukai, H. Tada, and Y. Ono Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan Eur Urol 45 2004 176 181
3. W. Oosterlinck, B. Lobel, G. Jakse, P.U. Malmstrom, M. Stockle, Sternberg C European Association of Urology (EAU) Working Group on Oncological Urology Guidelines on bladder cancer Eur Urol 41 2002 105 112
4. S. Scholl, P. Beuzeboc, and P. Pouillard Targeting HER 2 in other tumor types Ann Oncol 12 suppl 1 2001 S81 S87
5. E. Tzahar, H. Watterman, X. Chen, G. Levkowitz, D. Karunagaran, and S. Lavi A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor Moll Cell Biol 16 1996 5276 5287
6. G.D. Lewis, I. Figari, B. Fendly, W.L. Wong, P. Carter, and C. Gorman Differential responses of the human tumor cell lines to anti-p185HER 2 monoclonal antibodies Cancer Immunol Immunother 37 1993 255 263
7. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2 New Engl J Med 344 2001 783 792
8. B. Tetu, Y. Fradet, P. Allard, C. Veilleux, N. Roberge, and P. Bernard Prevalence and clinical significance of HER 2/neu, p53, and Rb expression in primary superficial bladder cancer J Urol 155 1996 1784 1788
9. K. Wester, A. Sjöström, M. de la Torre, J. Carlsson, and P.U. Malmstrom HER 2- a possible target for therapy of metastatic urinary bladder carcinoma Acta Oncologica 41 2002 282 288
10. K. Sato, M. Moriyama, S. Mori, M. Saito, T. Watanuki, and K. Terada An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma Cancer 70 1992 2493 2498
11. R. Gandour-Edwards, P.N. Lara Jr., A.K. Folkins, J.M. LaSalle, L. Beckett, and Y. Li Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95 2002 1009 1015
12. M. Hussain, D.C. Smith, and S. Al-Sushun Preliminary results of HER-2/neu screening and treatment with trastuzumab (herceptin) (T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in patients with advanced urothelial cancer J Clin Oncol 21 2002 A800
13. G. de Pinieux, D. Colin, A. Vincent-Salomon, J. Couturier, D. Amsellem-Ouazana, and P. Beuzeboc Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/neu (c-erbb-2) status in urothelial carcinoma Virchows Arch 444 2004 415 459
14. Z. Latif, A.D. Watters, I. Dunn, K. Grigor, M.A. Underwood, and J.M. Bartlett HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40 2004 56 63
15. D.J. Vaughn, J. Manola, R. Dreicer, W. See, R. Levitt, and G. Wilding Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group Cancer 95 2002 1002 1007